We fight to improve the lives
of everyone affected by epilepsy

US regulator approves liquid version of Keppra

29 Jul 2003

The US Food and Drug Administration (FDA) has approved grape-flavored, dye-free version of the anti-epileptic drug Keppra (levetiracetam) as an oral solution, providing a new option for patients with epilepsy who prefer a liquid or cannot swallow tablets.

Keppra tablets were approved by the FDA in November 1999 for the adjunctive treatment of partial onset seizures in adults with epilepsy, and Keppra oral solution, approved for the same indication, is expected to be available through pharmacies in the United States by the end of the year.

Professor Blanca Vazquez, assistant professor of neurology and director of clinical trials at New York University Comprehensive Epilepsy Center, commented:

"Keppra oral solution provides physicians with a new dosing option that may be ideal for patients who prefer the convenience of a liquid."